Learning objectives 1. Describe why, when, with whom, and where to use a vena cava filter
2. Discuss why imaging the vena cava is important 3. Compare and contrast “tried and true” vs state-of-the-art technology
4. Utilize appropriate techniques for placing and retrieving filters 5.Avoid complications in the use of vena cava filters.
6. Explore ways to build successful referral patterns.
This activity is supported by an educational grant from Cook Incorporated and has been designed for Interventional Cardiologists, Vascular Surgeons, Fellows and Interventional Cardiovascular Nurses and Technologists.
Module 1: Direct Thrombin Inhibition During Peripheral Vascular Interventions
Upon completion of this educational activity, participants should be able to:
1. Review the rationale to use direct thrombin inhibitors in the periphery
2. Review clinical data that support the use of bivalirudin in peripheral vascular interventions
Module 2: Use of Direct Thrombin Inhibitors during PPI for CLI, SFA and Fem-Pop Intervention
Upon completion of this educational activity, participants should be able to:
1. Discuss the clinical impact of CLI
2. Discuss the role of antithrombins therapy and anticoagulation in the role of limb salvage
Module 3: Adjunctive Pharmacology During Carotid Artery Stenting
Upon completion of this educational activity, participants should be able to:
1. discuss the basics of pharmacology in carotid stent placement including preparation, intraprocedural and post-stent medical therapy
2. review medical management of complications intraprocedurally during carotid stent placement
3. describe possible drug alternatives for future therapy
Complimentary ON - DEMAND Accredited Webcast
Topics 1. EVA-3S & Space-Bumps in the road 2. CAPTURE 3500-Lesion morphology & Predictors for Stroke 3. CAPTURE II vs. EXACT 1500-Does open or Closed Cell Stent design really matter?
This activity has been developed for Interventional Cardiologists, Vascular Surgeons, Interventional Radiologists, Neurologists, Interventional Nurses and Technologists with an interest in the diagnosis and treatment of peripheral artery disease.
Cath Lab News
FDA Approves Abbott’s Xience™ V Drug-Eluting Stent
The U.S. Food and Drug Administration (FDA) approved the Xience™ V everolimus-eluting coronary stent system for the treatment of coronary artery disease. Xience V is the only drug-eluting stent to have demonstrated superiority over Boston Scientific’s Taxus® paclitaxel-eluting coronary stent system in two randomized head-to-head clinical trials. Xience V will be launched in the United States immediately. Abbott also supplies a private-label version of Xience V to Boston Scientific called the Promus™ everolimus-eluting coronary stent system. Promus is designed and manufactured by Abbott and supplied to Boston Scientific as part of a distribution agreement between the two companies.
Obesity May Offer Some Protection After Stenting
Paradoxically, obesity may offer some protection against heart-related "events," like heart attack, in people who have a stent placed, research shows. In a study, researchers found that obese patients who had stents placed in diseased arteries had a lower incidence of adverse cardiac events than their normal-weight counterparts.
Coronary Arterial Calcium Scans Help Detect Overall Death risk in the Elderly
Measuring calcium deposits in the heart's arteries can help predict overall death risk in American adults, even when they are elderly, according to a new study published in the July issue of Journal of the American College of Cardiology.
Matthew J. Budoff, MD, one of the study's authors and a researcher at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), said previous studies had found measuring coronary arterial calcium with computed tomography (CT) heart scans could predict overall death risks in most American adults.
Contradicting some earlier reports, a new study finds that women who have heart attacks benefit as much as men from cardiac catheterization. But that benefit is seen only in women whose heart damage is severe enough to be classified as a heart attack, said study author Dr. Michelle O'Donoghue, a member of the TIMI Research Group at Brigham and Women's Hospital in Boston. Those who have suffered a "near heart attack" called unstable angina should be given more conservative treatment.
An interventional cardiology team led by Professor Patrick W. Serruys successfully placed a vProtect™ Luminal Shield, a self-expanding intracoronary prosthesis designed to limit arterial injury that typically occurs when stents are deployed, in the left anterior descending (LAD) coronary artery of a 64-year-old man at Erasmus Medical Center in Rotterdam. The Shield also provides robust biocompatible support for the vessel to ensure that the target coronary artery will remain patent after placement. This case marks the start of a pilot study, known as SECRITT I, designed to evaluate the vProtect™ Luminal Shield as a treatment for vulnerable plaques – atherosclerotic deposits in the coronary arteries that do not produce symptoms until they rupture with potentially fatal consequences. There are more than 500,000 sudden cardiac deaths in the U.S., and more than 300,000 in Europe, every year.
The P.A.D. Coalition, an alliance of leading health organizations united together to improve the health and health care of patients with P.A.D., has released new patient resources on P.A.D. including a series of Spanish language patient education resources available free for health care professionals and the general public.
Learn About STEMI Interventions. STEMI Interventions represent enormous challenges as well as tremendous opportunities for healthcare personnel involved in their management. The Textbook of STEMI Interventions presents comprehensive, state-of-the-art management of STEMI interventions with an emphasis on short door-to-balloon times. It contains contributions from top interventional cardiologists about global strategies for the transfer and triage of STEMI patients.
